Idorsia-led Portfolio
The company will develop each asset to the next inflection point or seek a partner.
| Compound | Mechanism of action | Target indication | Status | More Information |
|
QUVIVIQ™ (daridorexant) |
Dual orexin receptor antagonist |
Insomnia |
Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, and Sweden; approved throughout the EU | |
|
Lucerastat |
Glucosylceramide synthase inhibitor |
Fabry disease |
Phase 3 open-label extension study ongoing – kidney biopsy sub-study results expected in Q2 2025 – regulatory pathway to be further discussed with FDA | |
| Daridorexant | Dual orexin receptor antagonist | Pediatric insomnia | Phase 2 in pediatric insomnia ongoing | |
| ACT-777991 | CXCR3 antagonist | Vitiligo | Proof-of-concept study in preparation | |
|
ACT-1004-1239 |
ACKR3 (CXCR7) receptor antagonist | Progressive multiple sclerosis | Proof-of-concept study in preparation | |
|
IDOR-1117-2520 |
CCR6 receptor antagonist | Psoriasis | Proof-of-concept study in preparation | |
| ACT-1016-0707 | LPA 1 receptor antagonist | Immune-mediated and fibrosis related disorders | Entry-into-human package complete | |
| IDOR-1134-9712 | CFTR Type-IV corrector | Cystic Fibrosis | Entry-into-human package in progress | |
| IDOR-1126-6421 | Undisclosed mechanism | Organ injury / fibrosis | Entry-into-human package in progress | |
| IDOR-1141-8472 | Orexin 2 receptor agonist | Orexin-related CNS disorders | Entry-into-human package ready to begin |
| Synthetic Glycan Vaccine Platform | Idorsia will seek a partner for the platform or individual vaccines | ||
| IDOR-1134-2831 | Synthetic glycan vaccine | Clostridium difficile infection | Idorsia is conducting a Phase 1 clinical pharmacology study – Results expected in Q2 2025. |
| IDOR-1142-0810 | Synthetic glycan vaccine | Klebsiella pneumonia infection | Entry-into-human package in progress. |